Orchestra BioMed Holdings, Inc. financial statements
Income statement, balance sheet and cash flow statement for the last 5 fiscal years, taken from the XBRL data Orchestra BioMed Holdings, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
3.53
2.76
2.64
33.5
Cost of revenue
0.21
0.19
0.2
0.19
Gross profit
3.32
2.57
2.43
33.3
Research and development
21.9
33.8
42.8
58.2
Selling, general and administrative
14
20.3
23.9
26.9
General and administrative
0.27
2.96
Operating income
-0.39
-32.7
-51.5
-64.3
-51.8
Interest expense
1.3
1.4
0.3
Interest income
0.02
0.35
Other non-operating income
-0.01
Income tax
0
Net income
-0.38
-33.6
-49.1
-61
-52.7
EBITDA
-32.4
-51.2
-64
-51.5
EPS, basic
-0.26
-2.24
-1.48
-1.66
-1.11
EPS, diluted
-0.26
-2.24
-1.48
-1.66
-1.11
Shares, basic (weighted)
1.55
15
33.2
36.8
47.7
Shares, diluted (weighted)
1.55
15
33.2
36.8
47.7
Balance sheet
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
1.75
19.8
30.6
22.3
34.7
Short-term investments
63.9
57
44.6
71.8
Receivables
0.1
0.1
0.09
0.1
Inventory
0.28
0.15
0.17
0.31
Other current assets
0.05
0.53
1.27
2.09
0.99
Total current assets
1.8
84.7
89.1
69.2
108
Property, plant and equipment
1.49
1.28
1.38
1.72
Lease right-of-use assets
2.19
1.56
2.1
1.5
Long-term investments
3.3
4.9
Total assets
162
95.6
95.2
76.2
115
Accounts payable
0
3.97
2.9
5.13
6.1
Accrued liabilities
0.01
5.38
5.15
6.08
9.89
Deferred revenue
6.44
2.51
4.44
Total current liabilities
0.17
18.6
11.2
16.2
16.7
Lease liabilities
1.68
1.04
1.69
0.94
Other non-current liabilities
0.2
0.04
0.31
Total liabilities
5.77
43
27.2
43.2
51.5
Total debt
15
15
Paid-in capital
252
317
343
416
Retained earnings
-3.94
-200
-249
-310
-363
Other comprehensive income
-0.01
-0.01
0.05
0.06
Shareholders' equity
-19.8
52.5
Total equity
-19.8
52.5
68
33
53.6
Total liabilities and equity
162
95.6
95.2
76.2
115
Shares outstanding
0.34
20.2
35.8
38.2
57
Cash flow statement
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-0.38
-33.6
-49.1
-61
-52.7
Depreciation and amortization
0.22
0.29
0.31
0.33
Stock-based compensation
3.38
7.63
10.6
12
Change in receivables
0.03
-0
0.02
-0
Change in inventory
-0.21
0.13
-0.03
-0.14
Change in payables
-0.01
0.38
0.15
2.97
4.87
Cash from operations
-0.27
-29.3
-46.1
-50.6
-49
Capital expenditures
-0.59
-0.08
-0.29
-0.49
Purchases of investments
-63.3
-142
-72.6
-76.3
Sales and maturities of investments
153
86.6
49.9
Cash from investing
-64.1
10.7
13.1
-26.9
Debt issued
10
15
Debt repaid
-6.45
-10.8
Stock issued
0.12
0.23
0.24
0.09
Dividends paid
-20
Cash from financing
103
46.2
29.2
88.3
Net change in cash
-0.27
9.85
10.8
-8.3
12.4
Free cash flow
-29.9
-46.2
-50.8
-49.5
Interest paid
1.37
1.12
0.1
1.45
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $5.95 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
99.5%
Gross profit / revenue.
Operating margin
-181.4%
Operating income / revenue.
EBITDA margin
-180.3%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-184.6%
Net income / revenue.
FCF margin
-184.8%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-182.4%
Cash from operations / revenue.
Return on assets (ROA)
-51.0%
Net income / average total assets.
R&D / revenue
197.7%
Research and development expense / revenue.
SG&A / revenue
83.2%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
34.8%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
2.4%
Capital expenditures / revenue.
D&A / revenue
1.1%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
1,169.0%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
111.6%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit growth, 1y
1,268.0%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
115.6%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
50.8%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
6.3%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Share count change, 1y
29.7%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
47.1%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
8.26x
Current assets / current liabilities.
Quick ratio
8.17x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
8.16x
(Cash + short-term investments) / current liabilities.
Liabilities / assets
74.6%
Total liabilities / total assets.
Working capital
$97.8M
Current assets - current liabilities.
Efficiency
Metric
Value
How it is calculated
Asset turnover
0.28x
Revenue / average total assets.
Fixed asset turnover
15.6x
Revenue / average property, plant and equipment.
Inventory turnover
0.63x
Cost of revenue / average inventory.
Days inventory
581 days
365 x average inventory / cost of revenue.
Receivables turnover
627x
Revenue / average receivables.
Days sales outstanding
1 days
365 x average receivables / revenue.
Days payables
14,256 days
365 x average accounts payable / cost of revenue.
Cash conversion cycle
-13,674 days
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$0.93
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Market cap + total debt - cash - short-term investments.
P/S
11.2x
Market cap / revenue.
EV/Sales
7.75x
Enterprise value / revenue.
FCF yield
-16.5%
Free cash flow / market cap.
Earnings yield
-16.5%
Net income / market cap (the inverse of P/E).
What was Orchestra BioMed Holdings, Inc.'s revenue in fiscal 2025?
Orchestra BioMed Holdings, Inc. reported revenue of $33.5M for fiscal 2025, 1,169.2% higher than the year before.
Was Orchestra BioMed Holdings, Inc. profitable in fiscal 2025?
No. It reported a net loss of $52.7M.
How much free cash flow did Orchestra BioMed Holdings, Inc. generate in fiscal 2025?
Cash from operations of $49.0M minus capital expenditures of $489.0K left free cash flow of -$49.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.